<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5100">
  <stage>Registered</stage>
  <submitdate>28/04/2015</submitdate>
  <approvaldate>28/04/2015</approvaldate>
  <nctid>NCT02439749</nctid>
  <trial_identification>
    <studytitle>SPYRAL HTN-OFF MED Study</studytitle>
    <scientifictitle>Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL HTN-OFF MED)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SPYRAL HTN-OFF MED</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <healthcondition>Vascular Diseases</healthcondition>
    <healthcondition>Cardiovascular Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Symplicity Spyral multi-electrode renal denervation system
Treatment: surgery - Sham Procedure

Experimental: Renal Denervation - Renal angiography and Renal Denervation (Symplicity Spyral multi-electrode renal denervation system)

Sham Comparator: Sham Procedure - Renal angiography


Treatment: devices: Symplicity Spyral multi-electrode renal denervation system
After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.

Treatment: surgery: Sham Procedure
After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acute and chronic safety by evaluating incidence of Major Adverse Events</outcome>
      <timepoint>From baseline to 36 months post-procedure</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in systolic blood pressure as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)</outcome>
      <timepoint>From baseline to 36 months post-procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in office systolic blood pressure</outcome>
      <timepoint>From baseline to 36 months post-procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of achieving target office systolic blood pressure (SBP&lt;140 mmHg or &lt;130 mmHg for patients with diabetes or renal disease)</outcome>
      <timepoint>From 1 month to 36 months post-procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in office diastolic blood pressure</outcome>
      <timepoint>From baseline to 36 months post-procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in diastolic blood pressure as measured by 24-hour ABPM</outcome>
      <timepoint>From baseline to 36 months post-procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Individual has office systolic blood pressure (SBP) = 150 mmHg and &lt;180 mmHg and a
             diastolic blood pressure (DBP) = 90 mmHg after being off medications.

          -  Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP = 140
             mmHg and &lt; 170 mmHg.

          -  Individual is willing to discontinue current antihypertensive medications.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Individual lacks appropriate renal artery anatomy.

          -  Individual has estimated glomerular filtration rate (eGFR) of &lt;45.

          -  Individual has type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus.

          -  Individual has one or more episodes of orthostatic hypotension.

          -  Individual requires chronic oxygen support or mechanical ventilation other than
             nocturnal respiratory support for sleep apnea.

          -  Individual has primary pulmonary hypertension.

          -  Individual is pregnant, nursing or planning to become pregnant.

          -  Individual is being treated chronically (e.g. daily use) with non-steroidal
             anti-inflammatory drugs (NSAIDs). Aspirin therapy is allowed.

          -  Individual has experienced a myocardial infarction, unstable angina pectoris, syncope,
             or a cerebrovascular accident within three months of the screening period, or has
             widespread atherosclerosis, with documented intravascular thrombosis or unstable
             plaques.

          -  Individual works night shifts.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>170</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <hospital>St. Vincent's Hospital Melbourne - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3065 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>LÃ¼beck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tochigi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Exeter</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to obtain an assessment of the efficacy and safety of renal
      denervation in the absence of antihypertensive medications.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02439749</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Raymond Townsend, MD</name>
      <address>University of Pennsylvania</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>K Wandrey</name>
      <address />
      <phone />
      <fax />
      <email>rs.SpyralHTNClinical@medtronic.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>